FDA regulators send Avedro back to the drawing board, asking the company to provide more information about its light-based cross-linking therapy for patients with rare eye conditions.
Massachusetts ophthalmic devices maker Avedro has some issues to address before the company can move forward with an FDA New Drug Application for its light-based cross-linking product for treatment.
News Well, Drug-Device Combinations, Food & Drug Administration (FDA), New Drug Application (NDA), Optical/Ophthalmic, Regulatory/Compliance
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1eP2NRy
Cap comentari:
Publica un comentari a l'entrada